Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion

1 Jun 2020

Abstract excerpt

gene fusion is now a targetable biomarker for patients who may otherwise be devoid of satisfactory alternative treatment options. In this article, the safety and efficacy trials of each medication, and the initial and ongoing monitoring required for patients on these treatments will be discussed.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Neuroblastoma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33604102
DOI: 10.6004/jadpro.2020.11.4.9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene FusionPMID 33604102Read ↗

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusionSemantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

Safety of current treatment options for NTRK fusion-positive cancersSemantic proximity Read ↗

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancersSemantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read ↗

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in ChinaSemantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

[Diagnosis and therapy of tumors with NTRK gene fusion].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.